Journey Medical Corporation (NASDAQ: DERM) announced that results from a Phase 1 clinical trial evaluating its rosacea treatment Emrosi were ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE